Press release
Rare Disorders Series II (Hypoparathyroidism) Treatment Market is Expected to Reach $1.09 bn by 2026
The Hypoparathyroidism Treatment Market was valued at US$658.58 million in the year 2018 and is estimated to reach US$1.09 billion by 2026, at a CAGR of 7.57%.Hypoparathyroidism is classified as a rare endocrine disorder characterized by failure in producing the required amount of parathyroid hormone or the produced hormone cannot participate in biological activities. Generally, the parathyroid hormone regulates calcium and phosphorus in the blood, determines bone cell activity and bone growth. An abnormality in the parathyroid gland can result in hypocalcaemia, hyperphosphatemia, etc. The abnormality can be caused due to several factors that include the autoimmune process, surgical removal of the parathyroid gland, genetic abnormalities, or causes unknown (idiopathic).
The onset of hypoparathyroidism is around 43±5 years. The epidemiological data suggest that the disorder is more prevalent in western countries such as the US (37 per 100000), Denmark (22 per 100000), Norway (10.2 per 100000). Further, the ratio of hypoparathyroidism in female to male population is 3:1. In the US, the female population accounts for more than 71% of the total hypoparathyroidism population with the total number of cases already crossing 81000 by 2018. Among the affected population, 95% of the incidence can be attributed to postsurgical hypoparathyroidism. With a drastic change in the lifestyle and increasing geriatric population, the number of thyroid surgeries is increasing due to alterations in endocrine functions. In recent times, the patients are screened more for thyroid and parathyroid based disorders very frequently. The R&D companies are also investing more to identify the best treatment modalities to reduce the impact of the disorders. These factors are expected to drive market growth throughout the forecast period.
North America and European regions are expected to contribute more towards the market share with increasing disease prevalence, presence of key players in the region and more R&D investments. The APAC & LAMEA regions have contributed less. However, increasing lifestyle changes may increase the contribution of these regions to the market share.
The treatment for hypoparathyroidism is to maintain the serum calcium, phosphorus, and magnesium within the allowed range. The standard treatment comprises of vitamin D2 and D3 supplements, and calcium supplements. On a longer run, parathyroid hormone under the hormonal therapy regimen is prescribed. Vitamin D therapy leads the market share among the hypoparathyroidism treatment followed by parathyroid hormone therapy and calcium supplementation. The main challenge faced during treatment is the length of the treatment, adherence, efficacy, and effectiveness of the treatment as it is purely based on clinical judgment and experience.
Companies such as Takeda and Roche are major players in the market with more prescriptions on Natpara and Rocaltrol, respectively. But recently, Takeda had to call back Natpara in the US owing to the presence of rubber particulates originating from the rubber septum of the NATPARA cartridge. There are also companies Ascendis Pharma, Aerami Therapeutics, Extend Biosciences, Entera Bio, etc. which have drugs at various stages of development. To date, there are 92 clinical trials reported in clinicaltrials.gov for hypoparathyroidism.
Request for Sample Pages @ https://www.optimainsights.org/sample-request/207-hypoparathyroidism-treatment-market
The Hypoparathyroidism Market Report is segmented based on Drug Class (Parathyroid hormone, Vitamin D & Calcium Supplement), By Route of Administration (Oral & Parenteral), By Distribution Channel (Hospital, Retail & Online Pharmacies) and By Region (North America, Europe, APAC and LAMEA).
The Hypoparathyroidism market analytics report from Optima Insights is a part of the Second Series on Rare Disorders consisting of a detailed analysis on the epidemiology, products, pipeline drugs, key drivers & restraints, challenges, reimbursement policies on the inherited metabolic disorders that require more attention. Further, every part of the rare metabolic disorder series will cover 10 disorders categorized based on country prevalence and occurrence.
Research Scope
o Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
o Provides a Comparative Analysis of Key Marketed and Pipeline Products.
o Provides Key Information on Players involved.
o Provides a Complete Overview of Market Segments and the Regional Outlook.
o Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
History of the Hypoparathyroidism Market, 2015 to 2017
Forecast of the Hypoparathyroidism Market Growth till the year 2026
The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Hypoparathyroidism Market
Analysis of potential growth segments which will drive the market
Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Request for TOC @ https://www.optimainsights.org/request-toc/207-hypoparathyroidism-treatment-market
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: sales@optimainsights.org
https://www.optimainsights.org
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rare Disorders Series II (Hypoparathyroidism) Treatment Market is Expected to Reach $1.09 bn by 2026 here
News-ID: 1927184 • Views: …
More Releases from Optima insights Pvt Ltd
Endometriosis Treatment Market is Expected to Reach $3.43 bn by 2027
The Endometriosis Treatment Market was valued at US $2.64 billion in the year 2019 and is estimated to reach US $3.43 billion by 2027, at a CAGR of 3.36%.
The growth of tissue outside the uterus similar to lining of uterus (endometrium) refers to Endometriosis. Areas of endometrial tissue growth often occur in ovaries, fallopian tubes, peritoneum and outer surfaces of bladder, uterus, intestines, and rectum and rarely spread beyond pelvic…
Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn …
The Inflammatory Bowel Disease (IBD) treatment market share was US$ 11.38 Bn in the year 2018. The market is anticipated to grow at a rate of 3.94%, through the forecast period to reach US$ 15.5 Bn by the year 2027.
Inflammatory Bowel Disease (IBD) usually denotes disorders characterized by the inflammation in the digestive system. Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome are two different disorders that are often confused…
Polycystic Ovarian Syndrome (PCOS) Treatment Market is Expected to Reach $5.59 b …
The Polycystic Ovarian Syndrome (PCOS) Treatment Market was valued at US $3.74 billion in the year 2019 and is estimated to reach US $5.59 billion by 2027, at a CAGR of 5.18%.
Polycystic Ovarian Syndrome (PCOS), also referred to as Stein-Leventhal syndrome is a hormonal disorder characterized by enlarged ovaries and formation of numerous small cysts (fluid-filled sacs) on the outer edges of the ovaries. Symptoms of PCOS include irregular periods,…
Veterinary Vaccines Market is Expected to Reach $13.51 bn by 2027
The Veterinary Vaccines Market was valued at US $7.91 billion in the year 2018 and is estimated to reach US $13.51 billion by 2027, at a CAGR of 6.13%.
Generally, vaccines are effective in preventing infectious diseases. Veterinary vaccines especially reduce the burden of the disease in animals and also helps in preventing several zoonotic diseases also. There are four types of veterinary vaccines available depending on preparation type, they are…
More Releases for Hypoparathyroidism
Hypoparathyroidism Market Size, Development, Key Opportunity, Application & Fore …
The global hypoparathyroidism market was valued at approximately $1.3 billion in 2023 and is projected to reach around $2.5 billion by 2031. This represents a compound annual growth rate (CAGR) of about 8.8%.
Request a Free Sample Copy@ https://www.datalibraryresearch.com/sample-request/hypoparathyroidism-market-5438
With market research reports garnering immense significance in the speedily transforming market place, the team at Data Library Research endows with Hypoparathyroidism Market report in a way which is predicted. It comprehensively…
Hypoparathyroidism Drug Market: An Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to low calcium levels in the blood. This deficiency causes various complications, including muscle cramps, fatigue, and neurological issues. Managing hypoparathyroidism primarily involves calcium and vitamin D supplements, but newer treatments targeting PTH replacement therapy have emerged, providing more effective and sustainable solutions.
The development of hypoparathyroidism drugs represents a promising area of growth in the…
Hypoparathyroidism Drug Market Size, Share, Trends, Demand, Growth and Competiti …
"Hypoparathyroidism Drug Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Hypoparathyroidism Drug Market report includes basic, secondary and advanced information related to the global…
Hypoparathyroidism Drug Market Size, Share, Trends, Growth and Competitive Analy …
Hypoparathyroidism Drug Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Hypoparathyroidism Drug Market report includes basic, secondary and advanced information related to the global…
Hypoparathyroidism Treatment Market Size 2024 to 2031.
Market Overview and Report Coverage
Hypoparathyroidism is a rare condition where the parathyroid glands in the neck produce too little parathyroid hormone, resulting in low calcium levels in the blood. The primary treatment for hypoparathyroidism involves calcium and vitamin D supplementation, as well as hormonal therapy.
The future outlook for the Hypoparathyroidism Treatment Market is promising, with a projected growth rate of 20.00% during the forecasted period. This growth can…
Hypoparathyroidism Treatment Market Size, Share, Trends, Analysis and Forecast 2 …
The Global Hypoparathyroidism Treatment Market is poised to register a CAGR of over 8% during the forecast period 2020 to 2027.
Hypoparathyroidism occurs when the parathyroid glands does not produce enough hormone. Hyperparathyroidism can be caused by a number of factors, including injury or removal of the parathyroid glands, DiGeorge syndrome, an autoimmune disease, cancer radiation treatment, and low magnesium levels. The main function of parathyroid hormone is to regulate blood…
